MajorIntermediate-acting benzodiazepine hypnotic×Atypical antipsychotics
Updated · Methodology
Mechanism
Both drugs act on the central nervous system (CNS), and the main risk of the combination is additive CNS depression. According to the lormetazepam SmPC, antipsychotics (neuroleptics) may increase CNS depression when taken with lormetazepam (lormetazepam SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Quetiapine acts mainly on the CNS and causes somnolence and sedation (quetiapine SmPC, AEMPS, sections 4.4 and 4.5). Their metabolism differs. CYP3A4 is the main enzyme that metabolises quetiapine in the liver (quetiapine SmPC, AEMPS, section 5.2). Lormetazepam is almost entirely converted to its glucuronide and excreted in the urine (lormetazepam SmPC, AEMPS, section 5.2). The documents do not say that either drug changes the concentration of the other.
Symptoms
The documents describe no symptoms specific to this combination. Central nervous system (CNS) depression may increase, causing somnolence, dizziness, unsteadiness and, in older people, falls. In older people, lormetazepam increases the risk of falls because of ataxia, muscle weakness, dizziness and somnolence. In chronic respiratory insufficiency, lormetazepam carries a risk of respiratory depression (lormetazepam SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Quetiapine causes somnolence and sedation, as well as orthostatic hypotension with dizziness, usually during initial dose titration. Sleep apnoea syndrome has been reported in people taking quetiapine (quetiapine SmPC, AEMPS, section 4.4).
Management
The strictest document for this pair is the Spanish SmPC of a generic lormetazepam product. It states that lormetazepam lowers tolerance to other central nervous system (CNS) depressants, so these should be avoided or taken at lower doses (Lormetazepam Normon SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). The same SmPC lists antipsychotics among CNS depressants (Lormetazepam Normon SmPC, AEMPS, section 4.5). The SmPC of the Lormetazepam Kern Pharma generic says the same. The SmPC of the originator lormetazepam product and the quetiapine documents are less strict: they call for caution with other CNS depressants and centrally acting drugs (lormetazepam and quetiapine SmPCs, AEMPS, section 4.5; quetiapine label, US Food and Drug Administration, FDA, section 7.1). Lormetazepam is prescribed for the shortest possible time, usually a few days to 2 weeks. The maximum is 4 weeks, including the tapering period, and treatment continues beyond that only after reassessment. Older people receive a lower dose (lormetazepam SmPC, AEMPS, section 4.4). Lormetazepam is contraindicated in sleep apnoea syndrome, severe respiratory insufficiency and acute poisoning with neuroleptics (lormetazepam SmPC, AEMPS, section 4.3). In people with a history or risk of sleep apnoea, quetiapine is used with caution together with CNS depressants. This applies, for example, to men and to people who are overweight or obese (quetiapine SmPC, AEMPS, section 4.4). Fall risk is assessed when quetiapine is started and again during long-term treatment if other medicines could worsen somnolence and unsteadiness (quetiapine label, FDA, section 5.8). People are warned not to drive or operate hazardous machinery until they are sure that quetiapine does not impair their thinking or motor skills (quetiapine label, FDA, section 5.16). Alcohol is not recommended with lormetazepam (lormetazepam SmPC, AEMPS, section 4.5) and should be limited during quetiapine treatment (quetiapine label, FDA, section 7.1).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Seroquel (quetiapine) prescribing information (2026)– FDA label, H2-Pharma, LLC, DailyMed setid 8ae62aaf-f8c5-417f-baac-0098369ca322, revised 04/2026, section 7
- AEMPS: Ficha técnica: Seroquel 25 mg, quetiapina (nº registro 63054), secciones 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 63054, revisión 12/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Lormetazepam, Noctamid 1 mg (nº registro 56296), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 56296 (Noctamid 1 mg comprimidos, Teofarma), revisión 02/2022, secciones 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Lormetazepam Normon 1 mg (nº registro 63611), sección 4.4 (2022)– AEMPS, CIMA, nº registro 63611 (Lormetazepam Normon 1 mg comprimidos EFG, Laboratorios Normon), revisión 09/2022, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Lormetazepam Kern Pharma 1 mg (nº registro 73584), sección 4.4 (2021)– AEMPS, CIMA, nº registro 73584 (Lormetazepam Kern Pharma 1 mg comprimidos EFG), revisión 08/2021, secciones 4.4 y 4.5